Biogen MS Pill’s Early Sales May Help It Beat Estimates

The introduction of Biogen Idec Inc.’s multiple sclerosis pill, Tecfidera, outstripped the initial sales of competing drugs from Novartis AG and Sanofi, suggesting the treatment may beat estimates for the year.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.